STALEY CAPITAL ADVISERS’s Atara Biotherapeutics ATRA Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$574K	Hold	50,000	–	–	0.02%	128
2026 Q1	$237K	Hold	50,000	–	–	0.01%	161
2025 Q4	$905K	Hold	50,000	–	–	0.04%	117
2025 Q3	$717K	Sell	50,000 -25,000	-33%	-$288K	0.03%	125
2025 Q2	$579K	Sell	75,000 -5,000	-6%	-$36.5K	0.02%	133
2025 Q1	$475K	Buy	80,000 +30,000	+60%	+$262K	0.02%	142
2024 Q4	$666K	Buy	50,000 +10,000	+25%	+$105K	0.03%	124
2024 Q3	$325K	Hold	40,000	–	–	0.01%	155
2024 Q2	$340K	Hold	40,000	–	–	0.02%	151
2024 Q1	$694K	Hold	40,000	–	–	0.03%	121
2023 Q4	$513K	Hold	40,000	–	–	0.03%	132
2023 Q3	$1.48M	Buy	40,000 +10,000	+33%	+$445K	0.08%	84
2023 Q2	$1.21M	Buy	30,000 +12,000	+67%	+$679K	0.07%	94
2023 Q1	$1.3M	Hold	18,000	–	–	0.07%	92
2022 Q4	$1.48M	Hold	18,000	–	–	0.09%	84
2022 Q3	$1.7M	Buy	18,000 +1,000	+6%	+$112K	0.11%	74
2022 Q2	$3.31M	Buy	17,000 +5,000	+42%	+$816K	0.2%	59
2022 Q1	$2.79M	Buy	12,000 +2,000	+20%	+$637K	0.14%	73
2021 Q4	$3.94M	Hold	10,000	–	–	0.19%	65
2021 Q3	$4.47M	Hold	10,000	–	–	0.24%	62
2021 Q2	$3.89M	Hold	10,000	–	–	0.2%	61
2021 Q1	$3.59M	Buy	+10,000	New	+$4.42M	0.2%	62

Other funds holding ATRA

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

STALEY CAPITAL ADVISERS's ATRA Position: Q2 2026 in Review

STALEY CAPITAL ADVISERS held its Atara Biotherapeutics (ATRA) position steady in Q2 2026 at 50,000 shares worth $574K. The position accounts for 0.02% of the portfolio, ranked #128.

STALEY CAPITAL ADVISERS first reported a position in ATRA in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.47M in Q3 2021. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

STALEY CAPITAL ADVISERS held 50,000 shares of Atara Biotherapeutics worth $574K as of Q2 2026.
STALEY CAPITAL ADVISERS left its Atara Biotherapeutics share count unchanged in Q2 2026.
Atara Biotherapeutics made up 0.02% of STALEY CAPITAL ADVISERS's portfolio in Q2 2026, its #128 holding.
STALEY CAPITAL ADVISERS first reported a position in Atara Biotherapeutics in Q1 2021 and has held it in 22 quarters since.
STALEY CAPITAL ADVISERS's Atara Biotherapeutics position peaked at $4.47M in Q3 2021.
21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q2 2026, filed 11 Aug 2026.